Cart is empty Doctors around the world may soon have access to a new tool that could better predict whether individual cancer patients will benefit from immune checkpoint inhibitors—a type of immunotherapy—using only routine blood tests and clinical data.
Doctors around the world may soon have access to a new tool that could better predict whether individual cancer patients will benefit from immune checkpoint inhibitors—a type of immunotherapy—using only routine blood tests and clinical data.
Leave A Comment